Karen Smith Increases Stake in Context Therapeutics
Karen Smith purchased 45,000 shares of Context Therapeutics on June 24, 2026.
Key Points
- Karen Smith bought 45,000 shares of Context Therapeutics on June 24, 2026, with shares trading at $0.56.
- Context Therapeutics has a market cap of $51.5 million and a 52-week range of $0.55 to $3.62.
- Analysts maintain a strong buy consensus with price targets ranging from $4 to $9.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Karen Smith, an insider at Context Therapeutics Inc. (NasdaqCM: CNTX), bought 45,000 shares of the company on June 24, 2026. This transaction was not part of a planned purchase program. Shares of Context Therapeutics traded near $0.56 on Saturday.
Other Institutional Activity in Context Therapeutics
Several institutional investors are also active in Context Therapeutics. Soleus Capital Management, L.P. opened a new position with 6,963,141 shares, valued at about $18.2 million. Similarly, Octagon Capital Advisors LP initiated a stake with 5,250,000 shares, worth around $13.8 million. On the other hand, Blue Owl Capital Holdings LP reduced its holdings by 2,343,891 shares, ending with 5,089,015 shares worth approximately $13.3 million.
Context Therapeutics Inc. Stock Up 51.2%
Shares of NasdaqCM: CNTX traded near $0.56 on Saturday. Context Therapeutics has a market cap of approximately $51.5 million. The company has a beta of 1.611, indicating higher volatility compared to the market. Its 52-week range is between $0.55 and $3.62. The stock's 50-day moving average is $2.01, while the 200-day moving average is $1.78. Context Therapeutics has a current ratio of 8.955, showing strong liquidity, and a debt-to-equity ratio of 0.541.
$CNTX stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Context Therapeutics Inc.
On June 24, 2026, several insiders, including Karen Smith, Jennifer Evans Stacey, Andy Pasternak, Linda West, and Luke Nathaniel Walker, each bought 45,000 shares of Context Therapeutics. Additionally, Jennifer Lynn Minai-Azary, the Chief Financial Officer, purchased 275,000 shares on February 19, 2026.
Analysts Set New Price Targets
On June 16, 2026, Maxim Group maintained its buy rating on Context Therapeutics with a $4.00 price target. Earlier in March, D. Boral Capital and Piper Sandler maintained their buy ratings with targets of $9.00 and $7.00, respectively. The consensus among eight analysts is a strong buy, with a mean price target of $5.38.
About Context Therapeutics
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania. It focuses on developing treatments for solid tumors. The company's main product candidate, CTIM-76, is a bispecific antibody designed to target cancer cells. Led by CEO Martin A. Lehr, Context Therapeutics collaborates with Integral Molecular, Inc. to advance its cancer therapies. Founded in 2015, the company employs around 15 people.
Bottom Line
Insider purchases, like those by Karen Smith, often attract attention as they can signal confidence in the company's future. Context Therapeutics is a small player in the biotechnology sector, with a focus on innovative cancer treatments. Investors watch such filings closely, though it's important to remember that insider activity is just one piece of the puzzle.
Get Context Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $CNTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.